New combo therapy aims to boost immune attack on liver tumors
NCT ID NCT06133062
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding proton radiotherapy to standard immunotherapy (atezolizumab and bevacizumab) can better control advanced liver cancer that cannot be removed by surgery. About 45 participants will receive the combination treatment. The study will measure how long the cancer stays under control and monitor side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
atezolizumab and bevacizumab (immunotherapy and anti-angiogenic drugs) plus proton radiotherapy
What this could lead to
If successful, this combination could improve tumor control and survival for people with advanced liver cancer that cannot be surgically removed.
What could go wrong
This is a small, early-phase trial (45 participants) without a comparison group, so results may not be definitive. Side effects from the drugs and radiation are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA NON-RESECTABLE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chang Gung Memorial Hospital at Linkou
RECRUITINGTaoyuan City, Taiwan, 333, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••